Drusen, the yellowish deposits that build up under the retina, are one of the hallmark warning signs of age-related macular degeneration (AMD). Once they appear, they usually grow. In a new human trial, a combination of resveratrol, quercetin, and curcumin (RQC) was associated with the opposite: a measurable drop in drusen volume over two years. The result is intriguing, but it comes from a small, open-label study, so read the details before you rush to a supplement aisle.
This is human clinical research, not a mouse or petri-dish study. It is also an early-phase trial with real design limits, covered below.
What the researchers tested
The study, published in Translational Vision Science & Technology by Pfahler and Knepper (University of Illinois Chicago and Northwestern), was an open-label, randomized phase 2a trial. Patients with early or intermediate AMD were randomized 2:1 to take either:
- an oral combination of resveratrol, quercetin, and curcumin (RQC), or
- oral curcumin alone
Treatment lasted 24 months. The primary outcome was the change in central drusen volume from baseline, measured with spectral-domain optical coherence tomography (SD-OCT), a standard high-resolution retinal imaging method. Secondary outcomes covered drusen volume and number by baseline size, individual drusen response, best-corrected visual acuity (BCVA), frequency of vision loss, progression to advanced AMD, and safety.
The headline numbers
Thirty-eight patients were included in the final analysis. After 24 months:
- Central drusen volume fell 13.4% in the RQC group and rose 6.9% in the curcumin-only group (P = 0.02).
- BCVA rose by 0.8 letters with RQC and fell by 2.1 letters with curcumin (P = 0.08), so this difference did not reach statistical significance.
- Mild and moderate vision loss were both less frequent in the RQC group. The abstract gives no exact figures for this.
- Progression to advanced AMD occurred in 3.7% of RQC participants and 2.3% of eligible eyes in that group.
The authors conclude that RQC was associated with reduced drusen volume, low rates of progression to advanced AMD, and maintained visual acuity over 24 months.
Why drusen matter
Drusen are a visible marker of AMD risk and progression. Seeing them shrink on imaging is interesting because there are few options for early and intermediate disease. The authors frame the work as preliminary evidence that an oral therapy may reduce drusen burden and deserves further study.
Shrinking drusen is not the same as proven vision protection. The study's own vision data were not statistically significant, and drusen volume is a surrogate marker. Whether reducing it changes long-term outcomes is a question this trial cannot answer.
The fine print: limitations you should know
This is where the excitement should be tempered.
- Small sample. Only 38 patients were analyzed. Small trials can produce results that shrink or vanish in larger studies.
- No placebo group. The comparator was curcumin alone, not placebo. The trial therefore tests RQC against one of its own ingredients, not against doing nothing. It cannot tell us how RQC compares with no supplement. The curcumin group's drusen growth (+6.9%) also isn't a clean picture of natural progression.
- Open-label design. Participants and clinicians knew who was taking what, which can introduce bias, though SD-OCT measurements are relatively objective.
- Vision result not significant. The BCVA difference (P = 0.08) is a trend, not a confirmed benefit. A 0.8-letter gain versus a 2.1-letter loss is also small in absolute terms.
- Phase 2a. This phase is designed to explore signals and feasibility, not to establish efficacy.
- Missing detail in the abstract. Doses, formulations, and safety findings are not reported there, so they can't be assessed from the summary alone.
Where this fits with AREDS2
The established supplement standard for intermediate AMD remains the AREDS2 formulation, which was built on large-scale trial evidence. Nothing in this study replaces it. This trial didn't compare RQC with AREDS2, so it can't say whether the polyphenol stack is better, worse, or complementary. At this point RQC is a research signal, not a recommendation to swap regimens.
Practical takeaways
Dose: The abstract does not report doses or formulations, so they can't be stated here. Don't guess from over-the-counter labels. Absorption and dosing of these compounds vary widely between products, and the trial's regimen may not match what's on a shelf.
Timing: The intervention ran for 24 months of oral treatment. Any effect seen was over that long horizon, not weeks.
Who it may be relevant to: The participants had early or intermediate AMD. That is the only population this evidence speaks to, and even there it is preliminary. If you have AMD, discuss this research with your eye doctor, who can weigh it alongside AREDS2 and your own risk profile.
Who should skip self-experimenting:
- Anyone with advanced AMD, who wasn't the target population here and needs specialist-directed care.
- People who'd use this instead of recommended monitoring or established treatment.
- Anyone on prescription medications, especially blood thinners, or who is pregnant or has a chronic condition. Concentrated polyphenol supplements can interact with some drugs, so check with a clinician or pharmacist first.
- Anyone hoping for a proven fix. This is not one yet.
The bottom line
A resveratrol, quercetin, and curcumin combination was linked to a statistically significant reduction in central drusen volume (-13.4% vs +6.9%, P = 0.02) in a 24-month randomized trial of 38 people with early or intermediate AMD. The vision benefits didn't reach significance, there was no placebo arm, and the study was open-label. It's a promising hypothesis-generating result that justifies larger, blinded, placebo-controlled trials, not a reason to change your eye-care routine on your own.
